Toward uncertainty-aware clinical decision support for treatment response prediction in metastatic NSCLC: integrating FDG-PET, T-cell repertoire, and cytokines with conformal prediction.

Faisal Yaseen¹, Daniel S Hippe², Sunan Cui¹, Jie Fu¹, Yejin Kim¹, Clemens Grassberger¹, Lei Deng¹, Ting Ye¹, Paul E Kinahan¹, Jing Zeng¹, John H Gennari¹, Stephen R Bowen¹

¹University of Washington.

²Fred Hutch Cancer Center: Fred Hutchinson Cancer Center.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Variable response to chemoimmunotherapy in metastatic non-small cell lung cancer (mNSCLC), together with the limited discriminative accuracy of PD-L1 tumor proportion score, highlights the need for reliable, uncertainty-aware early response prediction using multimodal biomarkers. We developed and prototyped a multimodal clinical decision support (CDS) framework integrating longitudinal…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.